REFERENCES
- Hafner C, Vogt T, Landthaler M, et.al. Somatic FGFR3 and PIK3CA mutations are present in familial seborrheoeic keratoses. British J Dermatol. 2008;159:214-217.
- Wilmer EN, Gusafaon CJ, Ahn CS, et al. Most common dermatologic conditions encountered by dermatologists and nondermatologists. Cutis. 2014;94:285-292.
- Bickers DR, Lim HW, Margolis D, et.al. The burden of skin diseases: 2004 A joint project of the American Academy of Dermatology Association and the Society for Ivestigative Deramtology. J Am Acad Dermatol. 2006;55:490- 500.
- Gill D, Dorevitch A, Marks R. The prevalence of seborrheic keratoses in people aged 15 to 30 years: is the term senile keratosis redundant? Arch Dermatol. 2000;136:759-62.
- Rongioletti F, Corbella L, Rebora A. Multiple familial seborrheic keratoses. Dermatologica. 1988;176:43-45.
- Yeatman JM, Kilkenny M, Marks R. the prevalence of seborrhoeic keratoses in an Australian population: does exposure to sunlight play a part in their frequency? Br J Dermatol. 1997:137:411-14.
- Kwon OS, Hwang EJ, Bae JH, et al. Seborrheic keratosis in the Korean males: causative role of sunlight. Photodermatol Photoimmunol Photomed. 2003;19:73-80.
- Logie A, Dunois-Larde C, Rosty C, et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet. 2005;14(9):1153-1160.
- Stinco G, Errichetti P, Patrone P. Ungual seborrhoeic keratosis: report of a case and its dermoscopic features. J Eur Acad Dermatol Venereol. 2016;30:446-556.
- Del Rosso J. A closer look at seborrheic keratoses: patient perspectives, clinical relevance, medical necessity, and implications for management. J Clin Aesthetic Dermatol. 2017;10:16-25.
- Kyriakis, KP, Alexoudi I, Askoxylaki K, et al. Epidemiologic aspects of seborrheic keratosis. Int J Dermatol. 2012;51:233-237.
- Roh NK, Hahn HJ, Lee YW, et al. Clinical and histopathological investigation of seborrheic keratosis. Ann Dermatol. 2016;28(2):152-8.
- Niang SO, Kane A, Diall M, et al. Dermatosis papulos nigra in Dakar, Senegal. Int J Dermatol. 2007;46:45-47.
- Hafner C, Landthaler M, Mentzel T, et.al. FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra. Br J Dermatol. 2010;162(3):508-12.
- Chakradeo K, Narsinghpura K, Ekladious. Sign of Leser-Trelat. BMJ Case Rep 2016 AaPii:bcr2016215316. Doi:10.1136/bcr-2016-215316.
- Mathez ALG, Moroto D, Dib SA, Roberto de Sa J. Seborrheic keratoses and severe hypoinsulinemic hypoglycemia associated with insulin grow factor 2 secretion by a malignant solitary fibrous tumor. Diabetol Metab Sundr. 2016;8:33).
- Ginarte M, Garcia-Caballero T, Rernandez-Redondo V, et.al. Expression of growth hormone receptor in benign and malignant cutaneous proliferative entities. J Cutan Pathol. 2000;27:276-282.
- Izikson L, Sober AJ, Mihm MC, et.al. Prevalence of melanoma clinically resembling seborrheic keratosis: analysis on 9204 cases. Arch Dermatol. 2002;138:1562-6.
- Hafner C, Hartmann A, vanOers JMM, et.al. FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Modern Pathol. 2007;20:895-903.
- Hafner C, Toll A, Fernandez-Casado A, et al. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci USA. 2010;107:20780-5.
- Neel VA, Todorova K, Want J, et.al. Sustained Akt activity is required to maintain cell viability in seborheic keratosis, a benign epithelial tumor. J Invest Dermatol. 2016;136:696-705.
- Maize JC, Snider RL. Nonmelanoma skin cancers in association with seborrheic keratoses. Clinicopathologic correlations. Dermatol Surg. 1995;21:960- 962.
- Lin J, Han S, Cui L, et.al. Evaluation of dermoscopic algorithm for seborrheic keratosis: a prospective study in 412 patients. JEADV. 2014;28:957-962.
- Carrera C, Sequra S, Aquilera P, et al. Dermoscopic clues for diagnosing melanomas that resemble seborrheic keratosis. JAMA Dermatol. 2017; Doi:10.1001/jamadermatol 2017.0129.
- Conic RX, Napekoski K, Schuetx H, et al. The role of immunosuppression in squamous cell carcinomas arising in seborrheic keratosis. J Am Acad Dermatol. 2017 (In press; http://dx.doi.org/10.1016/j.jaad.2016.12.002)
- Kim W-J, Lee K, Song M, et al. Clinical clues for differential diagnosis between verruca plans and verruca plana-like seborrheic keratosis. J of Dermatol. 2015;42:373-377.
- Duque MI, Jordan JR, Fleischer AB, et al. Frequency of seborrheic keratosis biopsies in the United States: A benchmark of skin lesion care quality and cost effectiveness. Dermatol Surg. 2003;29:796-801.
- Herron MD, Bowen AR, Krueger GG. Seborrheic keratoses: A study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod. Int J Dermatol. 2004;43:300-2.
- Gurel MS, Aral BB. Effectiveness of erbium:YAG laser and cryosurgery in seborrheic keratoses: Randomized, prospective intraindividual comparison study. J Dermatol Treat. 2015;26(5):477-80.
- Cuevas P, Angulo J, Salgüero I, et al. Clearance of seborrhoeic keratoses with topical dobesilate. BMJ Case Rep. 2012;2012. pii: bcr0120125628.
- Levy-Nissenbaum E, Thio HB, Burstein P, et.al. Seborrheic keratosis removal in a multicentre phase I/II clinical trial using a novel topical formulation (BL- 5010). Br J Dermatol. 2015;173:247-249.
- Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition. https://www.drugs.com/clinical_trials/aclaris-therapeutics-announces-positive-top-line-phase-3-results-101-treating-seborrheic-keratosis-17248.html.
AUTHOR CORRESPONDENCE
Susan C. Taylor MD E-mail:................................................... [email protected]